Comments on the report of the hundred largest groups (600865): the revenue of 2017H1 dropped by 0.12% and the main business continued to be under pressure.
Comments on the quarterly report of the top 100 groups (600865): the net profit of homing in the first quarter was lower than expected and downgraded to "neutral".
Comments on the annual report of the hundred largest groups (600865): the net profit of returning to the mother fell by 34.27% compared with the same period last year, and continued to actively look for investment opportunities in large health industries.
Hundred Group (600865) comments: the main business is steady and actively explore the big health industry
[Shen Wan Hongyuan] hundred Group: three quarterly results are in line with expectations, continue to be optimistic about the company's medical transformation, and maintain the "buy" rating
Top 100 Group (600865) Quarterly report comments: the results of the three quarterly reports are in line with expectations and continue to be optimistic about the company's medical transformation and maintain its "buy" rating.
Comments on the quarterly results of the hundred largest groups (600865): the quarterly performance decline is lower than we expected, and the transformation is accelerated and the development prospect is promising.
[Shen Wan Hongyuan] Baida Group: the decline in performance in the first quarter is lower than we expected, the transformation is accelerated, and the development prospect is promising.
Comments on the annual report of the hundred largest groups (600865): the 2015 net profit of 141 million yuan is slightly lower than expected and is firmly optimistic about the transformation of the tumor industry chain.
Comments on the annual report of Baida Group (600865): the main business of traditional department stores stabilizes the transformation of medical and health care.
Top 100 Group (600865) Annual Report Review: Steady Management of Main Business and Continued Advancement of Healthcare
[Southwest Securities] Top 100 Group: Steady management of the main business, continuous advancement of healthcare
Top 100 Group (600865) Review: Development of Oncology Specialist Hospitals
Top 100 Group (600865) Comment: Establishing a Hong Kong Subsidiary to Accelerate the Process of International M&A in the Oncology Industry Chain and Maintain “Buying”
[Shenwan Hongyuan] Top 100 Group: Establishing a Hong Kong subsidiary to speed up the process of international mergers and acquisitions in the oncology industry chain and maintain “buying”
Top 100 Group (600865) Comment: The actual controller buys shares to boost confidence and continues to recommend the purchase of scarce cancer hospitals
[Shenwan Hongyuan] Top 100 Group: The actual controller buys shares to boost confidence and continues to recommend targets for scarce cancer hospitals
[Southwest Securities] Top 100 Group: Oncology Specialist Hospitals Scarce Targets
Top 100 Group (600865) review: Oncology specialist hospitals are scarce
Top 100 Group (600865) Review: Building High-end Cancer Hospital Retail+Medical Dual Wheel Drive
No Data